Sirolimus albumin bound

Drug Profile

Sirolimus albumin bound

Alternative Names: ABI-009; Nab-rapamycin; Nab-sirolimus

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abraxis BioScience
  • Developer AADi; Children's Oncology Group; National Cancer Institute (USA)
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Perivascular epithelioid cell tumours
  • Phase I/II Bladder cancer; Sarcoma
  • Phase I Pulmonary arterial hypertension; Solid tumours

Most Recent Events

  • 24 Aug 2017 Phase-I/II clinical trials in Sarcoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03190174)
  • 24 Jul 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Recurrent, Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA (IV) (NCT02975882)
  • 24 Jul 2017 Phase-I clinical trials in Solid tumours (In adolescents, In children, In infants, Recurrent, Second-line therapy or greater, In adults, Monotherapy) in USA (IV) (NCT02975882)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top